Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin

Toshiyuki Yamada, Juris Liepnieks, Merrill Benson, Barbara Kluve-Beckerman

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The development of amyloidotic diseases is believed to be determined in large part by the structure and metabolism of the amyloid subunit protein. The amino-terminal region of serum amyloid A (SAA), the subunit precursor protein in reactive amyloidosis, appears to confer fibrillogenic potential. Here we present data consistent with the hypothesis that amyloid A fibrillogenesis is favored when proteolysis of the amino-terminal region of SAA is impaired. Murine tissue extracts were found to contain pepstatin- inhibitable protease activity that cleaved mouse SAA2 between Glu8 and Ala9. Tissues obtained from mice that had been treated with pepstatin for 3 days lacked this activity. To investigate a possible relationship between inhibition of aspartic proteases and amyloidogenesis, mice were treated with pepstatin while concurrently undergoing a standard amyloid induction protocol (repeated casein injections). Pepstatin-treated mice showed amyloid deposition significantly sooner than the control group, which had received only casein. During the preamyloidotic phase, pepstatin-treated mice had higher concentrations of SAA in serum and spleen than control mice. In addition, clearance of injected 125I-labeled SAA from plasma was significantly delayed. Based on these findings, it is reasonable to postulate that inhibition of aspartic protease activity can lead to an accumulation of amino-terminally intact SAA molecules and thereby accelerate amyloid fibril formation.

Original languageEnglish
Pages (from-to)901-907
Number of pages7
JournalJournal of Immunology
Volume157
Issue number2
StatePublished - Jul 15 1996

Fingerprint

Serum Amyloid A Protein
Protease Inhibitors
Amyloid
Peptide Hydrolases
Caseins
Amyloidogenic Proteins
Tissue Extracts
Protein Subunits
Amyloidosis
Proteolysis
pepstatin
Spleen
Control Groups
Injections
Serum

ASJC Scopus subject areas

  • Immunology

Cite this

Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin. / Yamada, Toshiyuki; Liepnieks, Juris; Benson, Merrill; Kluve-Beckerman, Barbara.

In: Journal of Immunology, Vol. 157, No. 2, 15.07.1996, p. 901-907.

Research output: Contribution to journalArticle

Yamada, T, Liepnieks, J, Benson, M & Kluve-Beckerman, B 1996, 'Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin', Journal of Immunology, vol. 157, no. 2, pp. 901-907.
Yamada, Toshiyuki ; Liepnieks, Juris ; Benson, Merrill ; Kluve-Beckerman, Barbara. / Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin. In: Journal of Immunology. 1996 ; Vol. 157, No. 2. pp. 901-907.
@article{7ed42340374b499398d61df3deb63b47,
title = "Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin",
abstract = "The development of amyloidotic diseases is believed to be determined in large part by the structure and metabolism of the amyloid subunit protein. The amino-terminal region of serum amyloid A (SAA), the subunit precursor protein in reactive amyloidosis, appears to confer fibrillogenic potential. Here we present data consistent with the hypothesis that amyloid A fibrillogenesis is favored when proteolysis of the amino-terminal region of SAA is impaired. Murine tissue extracts were found to contain pepstatin- inhibitable protease activity that cleaved mouse SAA2 between Glu8 and Ala9. Tissues obtained from mice that had been treated with pepstatin for 3 days lacked this activity. To investigate a possible relationship between inhibition of aspartic proteases and amyloidogenesis, mice were treated with pepstatin while concurrently undergoing a standard amyloid induction protocol (repeated casein injections). Pepstatin-treated mice showed amyloid deposition significantly sooner than the control group, which had received only casein. During the preamyloidotic phase, pepstatin-treated mice had higher concentrations of SAA in serum and spleen than control mice. In addition, clearance of injected 125I-labeled SAA from plasma was significantly delayed. Based on these findings, it is reasonable to postulate that inhibition of aspartic protease activity can lead to an accumulation of amino-terminally intact SAA molecules and thereby accelerate amyloid fibril formation.",
author = "Toshiyuki Yamada and Juris Liepnieks and Merrill Benson and Barbara Kluve-Beckerman",
year = "1996",
month = "7",
day = "15",
language = "English",
volume = "157",
pages = "901--907",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin

AU - Yamada, Toshiyuki

AU - Liepnieks, Juris

AU - Benson, Merrill

AU - Kluve-Beckerman, Barbara

PY - 1996/7/15

Y1 - 1996/7/15

N2 - The development of amyloidotic diseases is believed to be determined in large part by the structure and metabolism of the amyloid subunit protein. The amino-terminal region of serum amyloid A (SAA), the subunit precursor protein in reactive amyloidosis, appears to confer fibrillogenic potential. Here we present data consistent with the hypothesis that amyloid A fibrillogenesis is favored when proteolysis of the amino-terminal region of SAA is impaired. Murine tissue extracts were found to contain pepstatin- inhibitable protease activity that cleaved mouse SAA2 between Glu8 and Ala9. Tissues obtained from mice that had been treated with pepstatin for 3 days lacked this activity. To investigate a possible relationship between inhibition of aspartic proteases and amyloidogenesis, mice were treated with pepstatin while concurrently undergoing a standard amyloid induction protocol (repeated casein injections). Pepstatin-treated mice showed amyloid deposition significantly sooner than the control group, which had received only casein. During the preamyloidotic phase, pepstatin-treated mice had higher concentrations of SAA in serum and spleen than control mice. In addition, clearance of injected 125I-labeled SAA from plasma was significantly delayed. Based on these findings, it is reasonable to postulate that inhibition of aspartic protease activity can lead to an accumulation of amino-terminally intact SAA molecules and thereby accelerate amyloid fibril formation.

AB - The development of amyloidotic diseases is believed to be determined in large part by the structure and metabolism of the amyloid subunit protein. The amino-terminal region of serum amyloid A (SAA), the subunit precursor protein in reactive amyloidosis, appears to confer fibrillogenic potential. Here we present data consistent with the hypothesis that amyloid A fibrillogenesis is favored when proteolysis of the amino-terminal region of SAA is impaired. Murine tissue extracts were found to contain pepstatin- inhibitable protease activity that cleaved mouse SAA2 between Glu8 and Ala9. Tissues obtained from mice that had been treated with pepstatin for 3 days lacked this activity. To investigate a possible relationship between inhibition of aspartic proteases and amyloidogenesis, mice were treated with pepstatin while concurrently undergoing a standard amyloid induction protocol (repeated casein injections). Pepstatin-treated mice showed amyloid deposition significantly sooner than the control group, which had received only casein. During the preamyloidotic phase, pepstatin-treated mice had higher concentrations of SAA in serum and spleen than control mice. In addition, clearance of injected 125I-labeled SAA from plasma was significantly delayed. Based on these findings, it is reasonable to postulate that inhibition of aspartic protease activity can lead to an accumulation of amino-terminally intact SAA molecules and thereby accelerate amyloid fibril formation.

UR - http://www.scopus.com/inward/record.url?scp=0029960572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029960572&partnerID=8YFLogxK

M3 - Article

C2 - 8752944

AN - SCOPUS:0029960572

VL - 157

SP - 901

EP - 907

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -